Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Moskowitz

Showing results (171-180 of 280) with videos related to

Pageof 28
Sort By:
Blood|August 11, 2005
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCLCraig H Moskowitz, Andrew D Zelenetz, Tarun Kewalramani, et al.
Blood|May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphomaPier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.
Journal of Clinical Psychopharmacology|August 1, 1990
A multicenter study of sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: executive summaryD Chen, D A Chernik, E Ellinwood, et al.
The Journal of Experimental Medicine|October 1, 1996
Beta 2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell 2 immune responsesD R Brown, D J Fowell, D B Corry, et al.
Bone Marrow Transplantation|January 14, 2009
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphomaB S Hoppe, C H Moskowitz, Z Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaC H Moskowitz, P A Hamlin, J Gabrilove, et al.
Leukemia & Lymphoma|September 7, 2000
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapyG B Donnelly, J Glassman, C Long, et al.
Leukemia & Lymphoma|July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphomaAndres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide ConditioningMichael Scordo, Valkal Bhatt, Meier Hsu, et al.
British Journal of Haematology|August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin, Carol S Portlock, David J Straus, et al.
Pageof 28

Showing results (171-180 of 280) with videos related to

Sort By:
Pageof 28
Blood|August 11, 2005
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCLCraig H Moskowitz, Andrew D Zelenetz, Tarun Kewalramani, et al.
Blood|May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphomaPier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.
Journal of Clinical Psychopharmacology|August 1, 1990
A multicenter study of sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: executive summaryD Chen, D A Chernik, E Ellinwood, et al.
The Journal of Experimental Medicine|October 1, 1996
Beta 2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell 2 immune responsesD R Brown, D J Fowell, D B Corry, et al.
Bone Marrow Transplantation|January 14, 2009
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphomaB S Hoppe, C H Moskowitz, Z Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaC H Moskowitz, P A Hamlin, J Gabrilove, et al.
Leukemia & Lymphoma|September 7, 2000
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapyG B Donnelly, J Glassman, C Long, et al.
Leukemia & Lymphoma|July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphomaAndres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide ConditioningMichael Scordo, Valkal Bhatt, Meier Hsu, et al.
British Journal of Haematology|August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin, Carol S Portlock, David J Straus, et al.
Pageof 28